Financials data is unavailable for this security.
View more
Year on year Adaptimmune Therapeutics PLC grew revenues 122.05% from 27.15m to 60.28m while net income improved from a loss of 165.46m to a smaller loss of 113.87m.
Gross margin | -- |
---|---|
Net profit margin | -51.25% |
Operating margin | -54.54% |
Return on assets | -21.81% |
---|---|
Return on equity | -65.04% |
Return on investment | -28.63% |
More ▼
Cash flow in USDView more
In 2023, Adaptimmune Therapeutics PLC increased its cash reserves by 34.14%, or 37.42m. Cash Flow from Investing totalled 176.54m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 140.88m for operations while cash generated from financing totalled 880.00k.
Cash flow per share | -0.2561 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.3765 |
---|---|
Tangible book value per share | 0.3726 |
More ▼
Balance sheet in USDView more
Current ratio | 3.09 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.2592 |
---|---|
Total debt/total capital | 0.2058 |
More ▼